Cardiol Therapeutics Statistics
Total Valuation
CRDL has a market cap or net worth of $200.79 million. The enterprise value is $182.42 million.
| Market Cap | 200.79M |
| Enterprise Value | 182.42M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CRDL has 116.82 million shares outstanding. The number of shares has increased by 28.88% in one year.
| Current Share Class | 116.82M |
| Shares Outstanding | 116.82M |
| Shares Change (YoY) | +28.88% |
| Shares Change (QoQ) | +5.46% |
| Owned by Insiders (%) | 3.03% |
| Owned by Institutions (%) | 13.05% |
| Float | 91.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 11.87 |
| P/TBV Ratio | 11.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.55, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.55 |
| Quick Ratio | 5.01 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -190.18% and return on invested capital (ROIC) is -124.20%.
| Return on Equity (ROE) | -190.18% |
| Return on Assets (ROA) | -90.92% |
| Return on Invested Capital (ROIC) | -124.20% |
| Return on Capital Employed (ROCE) | -148.81% |
| Weighted Average Cost of Capital (WACC) | 7.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.88% in the last 52 weeks. The beta is 0.61, so CRDL's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +56.88% |
| 50-Day Moving Average | 1.70 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 40.46 |
| Average Volume (20 Days) | 1,298,492 |
Short Selling Information
The latest short interest is 3.31 million, so 2.84% of the outstanding shares have been sold short.
| Short Interest | 3.31M |
| Short Previous Month | 2.93M |
| Short % of Shares Out | 2.84% |
| Short % of Float | 3.60% |
| Short Ratio (days to cover) | 1.98 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.25M |
| Pretax Income | -24.00M |
| Net Income | -24.00M |
| EBITDA | -25.24M |
| EBIT | -25.25M |
| Earnings Per Share (EPS) | -$0.24 |
Balance Sheet
The company has $18.37 million in cash and $75,345 in debt, with a net cash position of $18.29 million or $0.16 per share.
| Cash & Cash Equivalents | 18.37M |
| Total Debt | 75,345 |
| Net Cash | 18.29M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 16.92M |
| Book Value Per Share | 0.15 |
| Working Capital | 16.87M |
Cash Flow
In the last 12 months, operating cash flow was -$17.00 million and capital expenditures -$40,098, giving a free cash flow of -$17.04 million.
| Operating Cash Flow | -17.00M |
| Capital Expenditures | -40,098 |
| Depreciation & Amortization | 6,501 |
| Net Borrowing | -39,147 |
| Free Cash Flow | -17.04M |
| FCF Per Share | -$0.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRDL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -28.88% |
| Shareholder Yield | -28.88% |
| Earnings Yield | -11.95% |
| FCF Yield | -8.49% |
Analyst Forecast
The average price target for CRDL is $8.42, which is 392.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.42 |
| Price Target Difference | 392.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |